Pharmaceutical products | Tenderlake

Pharmaceutical products

Contract Value:
-
Notice Type:
Contract award notice
Published Date:
15 August 2024
Closing Date:
Location(s):
UKM SCOTLAND (UK UNITED KINGDOM)
Description:
Enzyme Replacement Therapy Medicines

Supply of Enzyme Replacement Therapy Medicines (a-d) to NHS Scotland:

- NP92624(a) Laronidase 500units/5ml solution for infusion vials 1 vial (Aldurazyme®)

- NP92624(b) Imiglucerase 400unit powder for solution for infusion vials 1 vial (Cerezyme®)

- NP92624(c) Agalsidase beta 35mg powder for solution for infusion vials 1 vial (Fabrazyme®)

- NP92624(c) Agalsidase beta 5mg powder for solution for infusion vials 1 vial (Fabrazyme®)

- NP92624(d) Alglucosidase alfa 50mg powder for solution for infusion vials 1 vial (Myozyme®)

The Framework Agreement is for the supply of Enzyme Replacement Therapy Medicines (a-d: Aldurazyme®/ Cerezyme®/ Fabrazyme®/ Fabrazyme®/ Myozyme®) to NHS Scotland. The Authority has awarded this framework as a Single supplier framework agreement to one (1) Framework Participant.

Awarded to:
NP92624 (a-d)
Aventis Pharma Ltd Trading As Sanofi, Reading (UK)
Download full details as .pdf
The Buyer:
The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
CPV Code(s):
33600000 - Pharmaceutical products